Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Galera Therapeutics Inc is a biotechnology business based in the US. Galera Therapeutics shares (GRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Galera Therapeutics employs 30 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $1.73 |
|---|---|
| 52-week range | $1.12 - $8.50 |
| 50-day moving average | $1.40 |
| 200-day moving average | $2.03 |
| Wall St. target price | $11.75 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.95 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.73 from 2022-09-29
| 1 week (2022-09-23) | 12.34% |
|---|---|
| 1 month (2022-09-01) | 34.11% |
| 3 months (2022-07-01) | 34.11% |
| 6 months (2022-03-31) | -27.31% |
| 1 year (2021-10-01) | -78.67% |
|---|---|
| 2 years (2020-10-01) | -82.36% |
| 3 years (2019-09-27) | N/A |
| 5 years (2017-09-27) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -42.47% |
| Return on equity TTM | -1063.11% |
| Profit margin | 0% |
| Book value | N/A |
| Market capitalisation | $41.6 million |
TTM: trailing 12 months
We're not expecting Galera Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Galera Therapeutics's shares have ranged in value from as little as $1.12 up to $8.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galera Therapeutics's is 2.0294. This would suggest that Galera Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Galera Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.